Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D2UE8B
|
|||
| Drug Name |
QPX7831
|
|||
| Indication | Gram-negative bacterial infection [ICD-11: 1B74-1G40] | Phase 1 | [1] | |
| Company |
Qpex Biopharma
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Staphylococcus Beta-lactamase (Stap-coc blaZ) | Target Info | Inhibitor | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT04578873) A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Ascending Single- and Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Oral QPX7831 in Healthy Adult Subjects. U.S.National Institutes of Health. | |||
| REF 2 | Selection of QPX7831, an Orally Bioavailable Prodrug of Boronic Acid beta-Lactamase Inhibitor QPX7728. J Med Chem. 2021 Dec 9;64(23):17523-17529. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.